
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
A massive undertaking to determine the sequence of the several billion DNA building blocks that represent the human genome is almost complete. Pediatricians can look forward to new molecular tests for diagnosing inherited disorders in the near future. Novel therapies should follow.






